94 related articles for article (PubMed ID: 30925530)
1. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion.
Chang CJ; Hsu WF; Jeng LB; Lai HC; Hsu SC; Chen TH; Wang HW; Peng CY
Curr Oncol; 2023 Nov; 30(12):10134-10141. PubMed ID: 38132371
[TBL] [Abstract][Full Text] [Related]
3. Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.
Saeki I; Yamasaki T; Yamauchi Y; Kawaoka T; Uchikawa S; Hiramatsu A; Aikata H; Kobayashi K; Kondo T; Ogasawara S; Chiba T; Kawano R; Chayama K; Kato N; Takami T
Cancer Med; 2023 May; 12(9):10625-10635. PubMed ID: 36951579
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib.
Sansone V; Tovoli F; Casadei-Gardini A; Di Costanzo GG; Magini G; Sacco R; Pressiani T; Trevisani F; Rimini M; Tortora R; Nardi E; Ielasi L; Piscaglia F; Granito A
Clin Transl Gastroenterol; 2021 Jan; 12(1):e00286. PubMed ID: 33443944
[TBL] [Abstract][Full Text] [Related]
5. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.
Kim N; Yu JI; Park HC; Yoo GS; Choi C; Hong JY; Lim HY; Lee J; Choi MS; Lee JE; Kim K
Cancer Immunol Immunother; 2021 Jun; 70(6):1593-1603. PubMed ID: 33231725
[TBL] [Abstract][Full Text] [Related]
6. Role of reimbursement and Physicians' awareness in the survival of sorafenib-eligible advanced hepatocellular carcinoma patients.
Huang HL; Chang TS; Canseco LM; Wu F; Lu SN
Kaohsiung J Med Sci; 2024 Jun; 40(6):589-598. PubMed ID: 38695728
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Qi X; Li J; Deng H; Li H; Su C; Guo X
Oncotarget; 2016 Jul; 7(29):45283-45301. PubMed ID: 27304193
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE.
Qu S; Wu D; Hu Z
Technol Cancer Res Treat; 2023; 22():15330338231206704. PubMed ID: 37849287
[No Abstract] [Full Text] [Related]
9. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy.
Jiang Y; Tu X; Zhang X; Liao H; Han S; Jiang W; Zheng Y; Zhao P; Tong Z; Fu Q; Qi Q; Shen J; Zhong L; Pan Y; Fang W
Support Care Cancer; 2020 Nov; 28(11):5569-5579. PubMed ID: 32361828
[TBL] [Abstract][Full Text] [Related]
10. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O; Demirel A; Hacıoğlu MB; Tastekin D; Karabulut S; Gündogdu A; Sever N; Ayhan M; Çelebi A; Majidova N; Yaşar A; Ağyol Y; Erel P; Kocaaslan E; Güren AK; Arıkan R; Isık S; Ercelep O; Goksu SS; Alandag C; Bilgetekin İ; Caner B; Sahin AB; Gulmez A; Akagunduz B; Kose F; Kaplan MA; Dogan E; Sakalar T; Guven DC; Gurbuz M; Ergun Y; Karaagac M; Turker S; Ozkul O; Yıldız B; Sahin S; Demiray AG; Sari M; Erdogan B; Hacıbekiroglu İ; Çakmak Öksüzoğlu ÖB; Kilickap S; Bilici A; Bayoglu İV; Topaloglu S; Cicin İ
J Chemother; 2024 Jan; ():1-9. PubMed ID: 38263804
[TBL] [Abstract][Full Text] [Related]
11. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
[TBL] [Abstract][Full Text] [Related]
12. Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis.
Rizzo A; Ricci AD; Fanizzi A; Massafra R; De Luca R; Brandi G
Curr Oncol; 2023 Jan; 30(1):749-757. PubMed ID: 36661706
[TBL] [Abstract][Full Text] [Related]
13. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.
Zhang X; Zhu X; Zhong J; Zhao Y; Zhang X; Zhang W; Ye F; Yang C; Xue J; Xiong R; Wang J; Shen S; Pan Y; Li D; Song T; Bi X; Sun H; Xiang B; Gu S; Wen T; Lu S; Chen Y; Yin T; Liu L; Kuang M; Xu L; Li D; Cai J
Sci Rep; 2024 Apr; 14(1):9745. PubMed ID: 38679630
[TBL] [Abstract][Full Text] [Related]
14. High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer.
Rich NE; Parvathaneni A; Sen A; Odewole M; Arroyo A; Mufti AR; Kerr TA; Grant L; Tujios SR; Mayo MJ; Lee WM; Yang JD; Yokoo T; Gopal P; Hoshida Y; Zhu H; Yopp AC; Marrero JA; Singal AG
Dig Dis Sci; 2022 Jun; 67(6):2666-2676. PubMed ID: 33939138
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib.
Yuan J; Liang H; Li J; Li M; Tang B; Ma H; Xie X; Yin X; Zhang L; Ren Z
Mol Clin Oncol; 2017 Nov; 7(5):837-842. PubMed ID: 29181175
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis.
Gu W; Tong Z
J Int Med Res; 2020 Aug; 48(8):300060520946872. PubMed ID: 32815430
[TBL] [Abstract][Full Text] [Related]
18. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
Hajiev S; Allara E; Motedayеn Aval L; Arizumi T; Bettinger D; Pirisi M; Rimassa L; Pressiani T; Personeni N; Giordano L; Kudo M; Thimme R; Park JW; Taddei TH; Kaplan DE; Ramaswami R; Pinato DJ; Sharma R
Br J Cancer; 2021 Jan; 124(2):407-413. PubMed ID: 33071284
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Wang H; Lin C; Fan W; Zhang J; Zhang Y; Yao W; Li J
Cancer Manag Res; 2020; 12():3433-3444. PubMed ID: 32523374
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study.
Hu Z; Hu Z; Zhan W; Wu W; Zhou Z; Chen M; Fu Y; Zhang Y
Int Immunopharmacol; 2024 Jan; 127():111413. PubMed ID: 38118318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
